89SrCl2联合99mTc-MDP治疗转移性骨癌临床疗效的系统评价

目的评价氯化锶联合99mTc-亚甲基二膦酸盐（联合组）治疗我国转移性骨癌临床疗效。方法计算机检索学术期刊网络出版总库、中国知网数据库（1994～2016 年）、中国万方数据库（1999～2016 年）、重庆维普中文科技期刊全文数据库（1989～2016 年）及中国生物医学文献数据库（1994～2016 年）数据库中关于联合组治疗我国转移性骨癌疗效的临床随机对照试验（RCT），对符合标准的RCT 进行Meta分析。结果共纳入16 篇RCT，1 366 例患者符合纳入标准。Meta分析结果，联合组治疗转移性骨癌的骨痛疗效、控制骨转移灶疗效、生存质量与单用氯化锶（对照组）治疗比较，差异有统计学意义（p <0.05），联合组优于对照组。两组不良反应比较，差异无统计学意义（p >0.05）。结论在常规对症支持治疗的基础上，联合组治疗转移性骨癌临床疗效确切，且优于对照组。

Systematic review of clinical effect of Strontium chloride combined with 99mTc-methylene diphosphonate on metastatic bone cancer in China

Objective To evaluate the clinical effect of combination therapy with Strontium chloride and 99mTc-methylene diphosphonate on metastatic bone cancer in China. Methods A comprehensive search was performed in CAJD, CNKI (1994-2016), WANFANG (1999-2016), VIP (1989-2016) and CB Mdisc (1994-2016) databases to collect the randomized controlled trials (RCTs) in which combined therapy with Strontium chloride and 99mTc-methylene diphosphonate was applied to metastatic bone cancer in China. Meta-analysiswas performed to analyze the RCTs. Results In the 16 RCTs which met the research standards, 1,366patients were analyzed. The meta-analysis results suggested that, compared with the Strontium chloride group,bone pain, bone metastasis control and life quality were improved significantly in the combination therapy group (p < 0.05); and the adverse reactions had no significant differences between the two groups (p > 0.05). Conclusions On the basis of symptomatic and supportive treatment, the effect of combined therapy of Strontium chloride and 99mTc-methylene diphosphonate is positive for treatment of metastatic bone cancer, and better than that of simple Strontium chloride treatment.